Coming Soon

As it absorbs data, gains agency, and intermediates between humans and reality, AI will help us to address enormous crises, from climate change to geopolitical conflicts to income inequality. It might well solve some of the greatest mysteries of our universe, revolutionize fields as diverse as medicine and architecture, and elevate the human spirit to unimaginable heights. But it will also pose challenges on a scale and of an intensity that we have never seen.

In this groundbreaking and provocative treatise, Alexander C. Karp, co-founder and chief executive officer of Palantir Technologies, and Nicholas W. Zamiska, head of corporate affairs at the company, offer a searing critique of our collective abandonment of creative and cultural ambition. They argue that in order for the West to maintain its geopolitical advantage—and the freedoms that we take for granted—the software industry must renew its commitment to addressing our most urgent challenges, including the new arms race of artificial intelligence.

Superagency offers a roadmap for using AI inclusively and adaptively to improve our lives and create positive change. While acknowledging challenges like disinformation and potential job changes, the book focuses on AI’s immense potential to increase individual agency and create better outcomes for society as a whole. Imagine AI tutors personalizing education for each child, researchers rapidly discovering cures for diseases like Alzheimer's and cancer, and AI advisors empowering people to navigate complex systems and achieve their goals

While traditional drugs mostly help us manage the effects of disease, cell therapies promise genuine cures for a broad range of intractable ailments, from Alzheimer’s to heart damage to cancer. They could even reverse the effects of aging. For the first time in history, on an unprecedented scale, we possess the power to modify the biology that gives rise to disease, ultimately restoring individuals to a state of normalcy and reversing debilitating ailments. Former FDA Commissioner Scott Gottlieb traces the scientific achievements that propelled progress in cell therapies.